Pediatric Gastroenterology, Hepatology & Nutrition

The Korean Society of Pediatric Gastroenterology, Hepatology and Nutrition (대한소아소화기영양학회)
권호 표지
DOI QR코드

DOI QR Code

Oral Vancomycin Therapy in a Child with Primary Sclerosing Cholangitis and Severe Ulcerative Colitis

  • Buness, Cynthia (National Patient Advocate Foundation, Paradise Valley) ;
  • Lindor, Keith D. (College of Health Solutions, Arizona State University) ;
  • Miloh, Tamir (Department of Gastroenterology, Hepatology and Nutrition, Texas Children's Hospital)
  • Received : 2015.11.05
  • Accepted : 2016.02.05
  • Published : 2016.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Primary sclerosing cholangitis (PSC), a rare progressive liver disease characterized by cholestasis and bile duct fibrosis, has no accepted, effective therapy known to delay or arrest its progression. We report a 15 year old female patient diagnosed with PSC and moderate chronic active ulcerative colitis (UC) who achieved normalization of her liver enzymes and bile ducts, and resolution of her UC symptoms with colonic mucosal healing, after treatment with a single drug therapy of the antibiotic oral vancomycin. We postulate that the oral vancomycin may be acting both as an antibiotic by altering the intestinal microbiome and as an immunomodulator. Oral vancomycin may be a promising treatment for PSC that needs to be further studied in randomized trials.

Keywords

References

  1. Tabibian JH, O'Hara SP, Lindor KD. Primary sclerosing cholangitis and the microbiota: current knowledge and perspectives on etiopathogenesis and emerging therapies. Scand J Gastroenterol 2014;49:901-8. https://doi.org/10.3109/00365521.2014.913189
  2. Bjornsson E, Olsson R, Bergquist A, Lindgren S, Braden B, Chapman RW, et al. The natural history of small-duct primary sclerosing cholangitis. Gastroenterology 2008;134:975-80. https://doi.org/10.1053/j.gastro.2008.01.042
  3. Lindor KD, Kowdley KV, Harrison ME; American College of Gastroenterology. ACG clinical guideline: primary sclerosing cholangitis. Am J Gastroenterol 2015;110:646-59. https://doi.org/10.1038/ajg.2015.112
  4. Miloh T, Arnon R, Shneider B, Suchy F, Kerkar N. A retrospective single-center review of primary sclerosing cholangitis in children. Clin Gastroenterol Hepatol 2009;7:239-45. https://doi.org/10.1016/j.cgh.2008.10.019
  5. Feldstein AE, Perrault J, El-Youssif M, Lindor KD, Freese DK, Angulo P. Primary sclerosing cholangitis in children: a long-term follow-up study. Hepatology 2003;38:210-7.
  6. Lindor KD, Kowdley KV, Luketic VA, Harrison ME, McCashland T, Befeler AS, et al. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009;50:808-14. https://doi.org/10.1002/hep.23082
  7. Abarbanel DN, Seki SM, Davies Y, Marlen N, Benavides JA, Cox K, et al. Immunomodulatory effect of vancomycin on Treg in pediatric inflammatory bowel disease and primary sclerosing cholangitis. J Clin Immunol 2013;33:397-406. https://doi.org/10.1007/s10875-012-9801-1
  8. Davies YK, Cox KM, Abdullah BA, Safta A, Terry AB, Cox KL. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 2008;47:61-7. https://doi.org/10.1097/MPG.0b013e31816fee95
  9. Tabibian JH, Weeding E, Jorgensen RA, Petz JL, Keach JC, Talwalkar JA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis-a pilot study. Aliment Pharmacol Ther 2013;37:604-12. https://doi.org/10.1111/apt.12232
  10. Davies YK, Tsay CJ, Caccamo DV, Cox KM, Castillo RO, Cox KL. Successful treatment of recurrent primary sclerosing cholangitis after orthotopic liver transplantation with oral vancomycin. Case Rep Transplant 2013;2013:314292.

Cited by

  1. Role of regulatory T cells in pathogenesis and therapy of autoimmune liver disease vol.27, pp.11, 2016, https://doi.org/10.11569/wcjd.v27.i11.665
  2. Primary Biliary Cholangitis and Primary Sclerosing Cholangitis vol.114, pp.10, 2016, https://doi.org/10.14309/ajg.0000000000000268
  3. A Personalized Approach to Managing Patients With an Ileal Pouch-Anal Anastomosis vol.6, pp.None, 2016, https://doi.org/10.3389/fmed.2019.00337
  4. Is Bartonella a Cause of Primary Sclerosing Cholangitis? A Case Study vol.2, pp.1, 2016, https://doi.org/10.3390/gidisord2010005
  5. Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework vol.115, pp.6, 2016, https://doi.org/10.14309/ajg.0000000000000604
  6. Chronic Antibiotic-Refractory Pouchitis: Management Challenges vol.14, pp.None, 2021, https://doi.org/10.2147/ceg.s219556
  7. The role of oral vancomycin in inducing remission for biologic-experienced ulcerative colitis with concomitant primary sclerosing cholangitis and liver transplantation vol.14, pp.1, 2021, https://doi.org/10.1007/s12328-020-01272-8
  8. Assessing and managing symptom burden and quality of life in primary sclerosing cholangitis patients vol.9, pp.2, 2016, https://doi.org/10.1080/21678707.2021.1898370
  9. Use of oral vancomycin in children with autoimmune liver disease: A single centre experience vol.13, pp.12, 2021, https://doi.org/10.4254/wjh.v13.i12.2113